CombiGene comments on positive news for Bluebird

An external expert committee has unanimously recommended FDA approval of two of Bluebird’s gene therapy treatments. Thus, the prospect for Bluebird to launch the treatments later this year looks likely. BioStock contacted Jan Nilsson, CEO of CombiGene, Sweden’s only listed gene therapy company, to get his view on the expert committee’s opinion.